date,title,source
Oct-30-18,"Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018",PR Newswire
Nov-05-18,Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman,PR Newswire
Nov-06-18,Audentes Therapeutics: 3Q Earnings Snapshot,Associated Press
Nov-06-18,Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update,PR Newswire
Nov-07-18,Audentes Therapeutics to Participate in Upcoming Investor Conferences,PR Newswire
Nov-09-18,"Recent Analysis Shows Audentes Therapeutics, Endocyte, Bluerock Residential Growth REIT, Air Products and Chemicals, BWX Technologies, and Modine Manufacturing Market Influences  Renewed Outlook, Key Drivers of Growth",GlobeNewswire
Nov-12-18,These Biopharmas Could Cure Genetic Diseases  At $5 Million Apiece,Investor's Business Daily
Nov-16-18,Edited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMT,Thomson Reuters StreetEvents
Dec-07-18,Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),PR Newswire
Dec-13-18,"Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay",American City Business Journals
Dec-18-18,"Is Audentes Therapeutics, Inc. (BOLD) Going to Burn These Hedge Funds?",Insider Monkey
Dec-21-18,"Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares",Simply Wall St.
Jan-02-19,Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference,PR Newswire
Jan-03-19,Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer,PR Newswire
Jan-04-19,Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),PR Newswire
Jan-07-19,Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities,PR Newswire
Jan-31-19,Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation,PR Newswire
Feb-05-19,Mizuho's 9 Best Biotech Stocks to Buy for 2019,Kiplinger
Feb-08-19,Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),PR Newswire
Feb-13-19,"Report: Developing Opportunities within Dunkin' Brands Group, Murphy Oil, NII, Audentes Therapeutics, RealNetworks, and MDC Partners  Future Expectations, Projections Moving into 2019",GlobeNewswire
Feb-20-19,Audentes Therapeutics to Participate in Upcoming Investor Conferences,PR Newswire
